Meuser Introduces Bill to Lower Prescription Drug Prices

WASHINGTON, D.C. - Yesterday, Congressman Dan Meuser (PA-09) introduced the Most Favored Patient Act, legislation that would build on President Trump's historic 'Great Healthcare Plan' to lower prescription drug costs and save billions of dollars for patients and taxpayers.

This bill incentivizes drug manufacturers to negotiate Most Favored Nation (MFN) pricing agreements with the Trump Administration. Manufacturers that decline to agree would be required to provide Medicare MFN pricing for five years.

Existing MFN agreements established under the Executive Order "Delivering Most Favored-Nation Prescription Drug Pricing to American Patients" would automatically satisfy the bill's requirements. The Most Favored Patient Act also creates a permanent framework to codify and enforce future cost-saving healthcare agreements as they are reached.

"For years, drug manufacturers charged Americans three times as much as patients abroad for the exact same prescription drugs, forcing our families and seniors to pick up the tab," Congressman Meuser said. "President Trump has taken action to end that unfair system by bringing drug companies to the table and making clear that Americans, as the world's largest purchasers of prescription drugs, deserve the lowest possible prices. With sixteen major manufacturers already on board, this policy is delivering real relief for patients who rely on treatments for diabetes, asthma, arthritis, and cancer. I am pleased to introduce legislation that locks in those savings, builds on this historic progress, and ensures lower drug prices for all Americans."

Background on MFN:

Since President Trump signed the order last May, his administration has secured agreements with 16 major pharmaceutical manufacturers to align U.S. drug prices with those paid by other developed countries. These agreements are expected to generate billions of dollars in savings by lowering negotiated drug costs in Medicare and Medicaid. The deals cover a variety of drugs and deliver significant cost reductions, including an 88% decrease in the cost of multiple sclerosis medication, a 90% decrease in the cost of Hepatitis C medication, and an 81% decrease in the cost of diabetes medicines.

Before this Executive Order, Americans paid nearly three times more than patients overseas for the same medications. President Trump's 'Great Healthcare Plan' ended that disparity. Congressman Meuser's legislation ensures those savings continue, so Americans receive the lowest possible prices as the world's largest purchasers of prescription drugs.

The full text of the legislation can be found here.

###